Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iodo-willardiine is a synthetic analog of the amino acid willardiine and acts as a highly potent and selective agonist for kainate receptors containing GluK1 (also known as GluR5) subunits. It exhibits high selectivity for these kainate receptor subtypes with an EC50 value of approximately 0.21 µM and shows minimal activity at AMPA receptors or other kainate receptor subunits such as GluK2, GluK6, or GluK7. Iodo-willardiine has been widely used in research to characterize the function of specific kainate receptor subtypes in neuronal signaling, apoptosis, necrosis, and neuropathic pain models. It is considered an experimental tool compound rather than a therapeutic drug[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iodo-willardiine.